![]() ![]() “Precision therapies continue to transform the treatment paradigm in oncology and acquiring a royalty on Gavreto aligns with our strategy of investing in differentiated therapies that address unmet medical needs. “We are pleased to partner with Blueprint and help advance their innovative precision therapy pipeline for the benefit of patients worldwide,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. RET fusions are implicated in approximately 1% to 2% of patients with NSCLC, 10% to 20% of patients with papillary thyroid cancer (PTC) and 90% of patients with advanced medullary thyroid cancer (MTC). RET activating fusions and mutations are key molecular drivers in multiple cancers and can be identified using diagnostic tests, including next-generation sequencing. Additionally, Gavreto has been submitted for marketing approval for thyroid cancers in Europe with a decision expected in the second half of 2022. Gavreto, marketed by Roche in certain markets outside the United States and Greater China, is a once-daily rearranged during transfection (RET) targeted therapy approved in Europe in November 2021 for the treatment of certain RET-altered non-small cell lung cancers (NSCLC). royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based milestones. NEW YORK, NY, JRoyalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. ![]() Blueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments.Attractive, precision oncology therapy with long patent duration added to portfolio. ![]()
0 Comments
Leave a Reply. |